Table 2 Longitudinal analysis of... | American Society of Hematology

Table 2

Longitudinal analysis of imatinib response in bone marrow subfractions

CML-Dx patient		Diagnosis				Remission after 3 mo of IM treatment
Patient no.	Sex, age, y	BCR-ABL+ FISH from pooled CFUs, %				BCR-ABL^IS in PB,%	BCR-ABL + FISH from pooled CFUs, %
Patient no.	Sex, age, y	HSC	CMP	GMP	MEP		HSC	CMP	GMP	MEP
10*	F, 39	90	86	81	70	CCyR (0.47)	30	20	30	25
11*	M, 48	87	68	72	76	CCyR (0.27)	46	29	32	30
12*	M, 48	91	85	72	70	1/12 Ph⁺ (n.a.)	24	32	28	16

CML-Dx patient		Diagnosis				Remission after 3 mo of IM treatment
Patient no.	Sex, age, y	BCR-ABL+ FISH from pooled CFUs, %				BCR-ABL^IS in PB,%	BCR-ABL + FISH from pooled CFUs, %
Patient no.	Sex, age, y	HSC	CMP	GMP	MEP		HSC	CMP	GMP	MEP
10*	F, 39	90	86	81	70	CCyR (0.47)	30	20	30	25
11*	M, 48	87	68	72	76	CCyR (0.27)	46	29	32	30
12*	M, 48	91	85	72	70	1/12 Ph⁺ (n.a.)	24	32	28	16

IS indicates international scale; PB, peripheral blood; F, female; M, male; n.a., not available; and HSC, lin⁻CD34⁺CD38⁻ cells, enriched for stem cells.

CML-Dx patients (see supplemental Table 1) were treated for 3 months with IM.

View Large

This Feature Is Available To Subscribers Only